<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 18 Mar 2025 20:11:50 +0000</lastbuilddate>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Cognitive Function and Patient-Reported Outcomes After Cardiogenic Shock</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100175/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 10:S0735-1097(25)00483-8. doi: 10.1016/j.jacc.2025.02.023. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40100175</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.023>10.1016/j.jacc.2025.02.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100175</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Eric J Hall</dc:creator>
<dc:creator>Jeff Schaffert</dc:creator>
<dc:creator>Sachin Agarwal</dc:creator>
<dc:creator>Colby R Ayers</dc:creator>
<dc:creator>Alexandra V Sykes</dc:creator>
<dc:creator>Laura H Lacritz</dc:creator>
<dc:creator>Amil M Shah</dc:creator>
<dc:creator>E Wesley Ely</dc:creator>
<dc:creator>C Munro Cullum</dc:creator>
<dc:creator>Maryjane A Farr</dc:creator>
<dc:creator>James A de Lemos</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cognitive Function and Patient-Reported Outcomes After Cardiogenic Shock</dc:title>
<dc:identifier>pmid:40100175</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.023</dc:identifier>
</item>
<item>
<title>2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock: A Report of the American College of Cardiology Solution Set Oversight Committee</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100174/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 12:S0735-1097(25)00418-8. doi: 10.1016/j.jacc.2025.02.018. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100174/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40100174</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.018>10.1016/j.jacc.2025.02.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100174</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Shashank S Sinha</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>Navin K Kapur</dc:creator>
<dc:creator>Rachna Kataria</dc:creator>
<dc:creator>Robert O Roswell</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock: A Report of the American College of Cardiology Solution Set Oversight Committee</dc:title>
<dc:identifier>pmid:40100174</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.018</dc:identifier>
</item>
<item>
<title>Managing Cardiogenic Shock Caused by Acute Myocardial Infarction: Invisible Challenges Revealed in a Statewide Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100173/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 10:S0735-1097(25)05209-X. doi: 10.1016/j.jacc.2025.02.027. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100173/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40100173</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.027>10.1016/j.jacc.2025.02.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100173</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Eric P Cantey</dc:creator>
<dc:creator>Aaron Lopacinski</dc:creator>
<dc:creator>Milan Seth</dc:creator>
<dc:creator>David E Hamilton</dc:creator>
<dc:creator>Elias J Dayoub</dc:creator>
<dc:creator>Siddharth Gandhi</dc:creator>
<dc:creator>Mir B Basir</dc:creator>
<dc:creator>Amir Kaki</dc:creator>
<dc:creator>Ryan D Madder</dc:creator>
<dc:creator>Devraj Sukul</dc:creator>
<dc:creator>Hitinder S Gurm</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Managing Cardiogenic Shock Caused by Acute Myocardial Infarction: Invisible Challenges Revealed in a Statewide Registry</dc:title>
<dc:identifier>pmid:40100173</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.027</dc:identifier>
</item>
<item>
<title>Respiratory Syncytial Virus and Incidence of Cardiovascular Events: A Nationwide Self-Controlled Case Series Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100172/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 10:S0735-1097(25)05260-X. doi: 10.1016/j.jacc.2025.02.031. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100172/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40100172</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.031>10.1016/j.jacc.2025.02.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100172</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mats C Højbjerg Lassen</dc:creator>
<dc:creator>Daniel Modin</dc:creator>
<dc:creator>Niklas Dyrby Johansen</dc:creator>
<dc:creator>Pradeesh Sivapalan</dc:creator>
<dc:creator>Anders Hviid</dc:creator>
<dc:creator>Tyra Grove Krause</dc:creator>
<dc:creator>Jens Ulrik Stæhr Jensen</dc:creator>
<dc:creator>Tor Biering-Sørensen</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Respiratory Syncytial Virus and Incidence of Cardiovascular Events: A Nationwide Self-Controlled Case Series Analysis</dc:title>
<dc:identifier>pmid:40100172</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.031</dc:identifier>
</item>
<item>
<title>Best Practices for Transforming Cardiovascular Care Delivery and Implementation: A Modern Framework</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100171/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 10:S0735-1097(25)00468-1. doi: 10.1016/j.jacc.2025.02.020. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100171/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40100171</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.020>10.1016/j.jacc.2025.02.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100171</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ami B Bhatt</dc:creator>
<dc:creator>Ginger K Biesbrock</dc:creator>
<dc:creator>Cathleen Biga</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Best Practices for Transforming Cardiovascular Care Delivery and Implementation: A Modern Framework</dc:title>
<dc:identifier>pmid:40100171</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.020</dc:identifier>
</item>
<item>
<title>Systolic Blood Pressure and Cardiovascular Mortality in U.S. Adults Aged 80+ Taking Antihypertensive Medications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100170/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 26:S0735-1097(25)00335-3. doi: 10.1016/j.jacc.2025.01.033. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100170/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40100170</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.033>10.1016/j.jacc.2025.01.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100170</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Huanhuan Yang</dc:creator>
<dc:creator>Chenxi Huang</dc:creator>
<dc:creator>Mitsuaki Sawano</dc:creator>
<dc:creator>Jeph Herrin</dc:creator>
<dc:creator>Guochong Chen</dc:creator>
<dc:creator>Zhihui Li</dc:creator>
<dc:creator>Erica S Spatz</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:creator>Yuan Lu</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Systolic Blood Pressure and Cardiovascular Mortality in U.S. Adults Aged 80+ Taking Antihypertensive Medications</dc:title>
<dc:identifier>pmid:40100170</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.033</dc:identifier>
</item>
<item>
<title>Use of Cardiac Rehabilitation in Older Patients with Myocardial Infarction Complicated by Cardiogenic Shock</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 12:S0735-1097(25)05893-0. doi: 10.1016/j.jacc.2025.03.497. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40099778</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.497>10.1016/j.jacc.2025.03.497</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099778</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mohammed Essa</dc:creator>
<dc:creator>Sérgio R R Decker</dc:creator>
<dc:creator>Lichen Liang</dc:creator>
<dc:creator>Yang Song</dc:creator>
<dc:creator>Merilyn S Varghese</dc:creator>
<dc:creator>Jose F Figueroa</dc:creator>
<dc:creator>Laurence Sperling</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Steven J Keteyian</dc:creator>
<dc:creator>Michael P Thompson</dc:creator>
<dc:creator>Alexis Beatty</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Use of Cardiac Rehabilitation in Older Patients with Myocardial Infarction Complicated by Cardiogenic Shock</dc:title>
<dc:identifier>pmid:40099778</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.497</dc:identifier>
</item>
<item>
<title>Effect of Targeting apoC-III with Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: Plozasiran induced reductions in apoC-III and showed potentially favorable quantitative and qualitative changes in lipoproteins as assessed by NMR in patients with hypertriglyceridemia and mixed hyperlipidemia. Plozasiran reduced TRL-P by ∼50%, shifted LDL to larger particles, and modestly increased HDL-P concentration. While high-potency TRL-lowering therapies can lead to an overall LDL-C increase, plozasiran did not increase LDL-P or apoB but shifted LDL particle size distribution...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 12:S0735-1097(25)05892-9. doi: 10.1016/j.jacc.2025.03.496. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Plozasiran, an investigational siRNA targeting hepatic apoC-III, reduces triglyceride-rich lipoproteins (TRLs). The impact of plozasiran on lipoprotein particle numbers and sizes is unknown. However, reductions in the number of TRL particles (TRL-P) and a shift to possibly less atherogenic large low-density lipoprotein particles (LDL-P) are expected.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To determine the impact of plozasiran on lipoprotein particle concentration and subclass distribution using nuclear magnetic resonance (NMR) in two phase 2 studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients (N=403) from SHASTA-2 (severe hypertriglyceridemia) and MUIR (mixed hyperlipidemia) were administered 2 total subcutaneous doses of plozasiran (10, 25, or 50 mg) or placebo at baseline and week 12. Comprehensive lipoprotein profiling was conducted with NMR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In SHASTA-2, there was a dose-dependent reduction in TRL-P, with placebo-adjusted total TRL-P reductions of -46% and reductions across all TRL subclasses with plozasiran. While total LDL-P was unchanged, large LDL-P concentration increased by +53% and medium by +56%; small LDL-P trended lower (-13%). Total HDL-P increased by +8%, primarily driven by a +36% increase in large high-density lipoprotein particles (HDL-P). Similarly, in MUIR, there were dose-dependent reductions in TRL-P, with total TRL-P significantly reduced by -48% (pooled plozasiran) and reductions across all TRL subclasses with plozasiran. While total LDL-P was unchanged, large and medium LDL-P levels increased by +88% and +46%, respectively; small LDL-P levels decreased by -28%. Total HDL-P increased by +12%, driven by a +83% increase in large HDL-P.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: Plozasiran induced reductions in apoC-III and showed potentially favorable quantitative and qualitative changes in lipoproteins as assessed by NMR in patients with hypertriglyceridemia and mixed hyperlipidemia. Plozasiran reduced TRL-P by ∼50%, shifted LDL to larger particles, and modestly increased HDL-P concentration. While high-potency TRL-lowering therapies can lead to an overall LDL-C increase, plozasiran did not increase LDL-P or apoB but shifted LDL particle size distribution from small dense LDL towards larger sizes. The ∼50% reduction in TRL-P with no increase in apoB and possibly beneficial qualitative changes in LDL suggests the potential of plozasiran to lower cardiovascular risk, which may be evaluated in a prospective outcomes trial.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40099777</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.496>10.1016/j.jacc.2025.03.496</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099777</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>Robert A Hegele</dc:creator>
<dc:creator>Rong Zhou</dc:creator>
<dc:creator>Stacey Melquist</dc:creator>
<dc:creator>Jennifer Hellawell</dc:creator>
<dc:creator>Nicholas J Leeper</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of Targeting apoC-III with Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia</dc:title>
<dc:identifier>pmid:40099777</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.496</dc:identifier>
</item>
<item>
<title>Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099776/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Vutrisiran demonstrated evidence of benefit across the range of baseline disease severities in HELIOS-B, with the greatest benefit in earlier, less severe disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 11:S0735-1097(25)05823-1. doi: 10.1016/j.jacc.2025.03.477. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Vutrisiran reduced the risk of all-cause mortality (ACM) and recurrent cardiovascular (CV) events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in HELIOS-B (NCT04153149).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To assess the effect of vutrisiran in HELIOS-B patients with different heart failure severities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: HELIOS-B randomized ATTR-CM patients with NYHA class I-III (class IV or class III with National Amyloidosis Centre [NAC] stage III were excluded) 1:1 to vutrisiran 25 mg or placebo every 3 months for up to 36 months. This exploratory subgroup analysis assessed the primary composite endpoint of ACM and recurrent CV events, ACM, and additional functional and biomarker endpoints.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 654 patients, 84 (13%), 508 (78%), and 62 (9%) were in NYHA class I, II, and III, respectively. Median baseline NT-proBNP level was 1,920 ng/L. Lower risk of ACM and recurrent CV events was observed with vutrisiran versus placebo across baseline severity subgroups: Respective hazard ratios (95% CIs): 0.54 (0.27, 1.10), 0.77 (0.57, 1.03), and 0.68 (0.33, 1.41) in NYHA class I, II, and III,; 0.52 (0.30, 0.88), 0.61 (0.37, 1.00) and 0.93 (0.64, 1.35) in NT-proBNP tertiles (&lt;1,368 ng/L, ≥1,368 and &lt; 2,691 ng/L and ≥2,691 ng/L); 0.49 (0.34, 0.72) and 1.07 (0.74, 1.56) in NAC Stage I and II/III; and 0.69 (0.45, 1.07) and 0.74 (0.53, 1.02) in Columbia early and intermediate/late stage. Similar effects were observed in the monotherapy population (patients not on tafamidis at baseline) and across the additional endpoints evaluated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Vutrisiran demonstrated evidence of benefit across the range of baseline disease severities in HELIOS-B, with the greatest benefit in earlier, less severe disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099776/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40099776</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.477>10.1016/j.jacc.2025.03.477</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099776</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mathew S Maurer</dc:creator>
<dc:creator>Ronald M Witteles</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Farooq H Sheikh</dc:creator>
<dc:creator>Caroline Morbach</dc:creator>
<dc:creator>Daniel Rodriguez Duque</dc:creator>
<dc:creator>Emre Aldinc</dc:creator>
<dc:creator>Satish A Eraly</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy</dc:title>
<dc:identifier>pmid:40099776</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.477</dc:identifier>
</item>
<item>
<title>More Than an Infant's Respiratory Illness: The Unfolding Cardiovascular Consequences of RSV in Older Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099775/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 6:S0735-1097(25)05338-0. doi: 10.1016/j.jacc.2025.03.007. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099775/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40099775</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.007>10.1016/j.jacc.2025.03.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099775</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Pekka J Vartiainen</dc:creator>
<dc:creator>Yuan Huang</dc:creator>
<dc:creator>Mitsuaki Sawano</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>More Than an Infant's Respiratory Illness: The Unfolding Cardiovascular Consequences of RSV in Older Adults</dc:title>
<dc:identifier>pmid:40099775</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.007</dc:identifier>
</item>
<item>
<title>Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099774/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Vutrisiran maintained or improved functional capacity, health status, and QOL in more patients with ATTR-CM versus placebo over 30 months.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 8:S0735-1097(25)05796-1. doi: 10.1016/j.jacc.2025.03.454. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) progressively impairs functional capacity, health status, and quality of life (QOL). In HELIOS-B, vutrisiran reduced all-cause mortality and recurrent cardiovascular events compared with placebo in patients with ATTR-CM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To further analyze vutrisiran's efficacy on functional capacity, health status, and QOL.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients were randomized 1:1 to receive vutrisiran 25 mg or placebo every 12 weeks up to 36 months. 6-minute walk test (6-MWT) and Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) were completed at baseline and every 6 months. Cutoff values for worsening were a decrease from baseline of >;7 m, >;15 m, and >;35 m (6-MWT), and >;5 and >;10 points (KCCQ-OS). Additionally, change from baseline was analyzed in prespecified subgroups and KCCQ subdomains.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the overall population at Month 30, greater proportions of patients treated with vutrisiran versus placebo had maintained or improved 6-MWT distance according to all cutoffs analyzed (>;7 m [49.6% vs 33.2%], >;15 m [55.5% vs 38.6%], and >;35 m [68.4% vs 51.6%]; all P&lt;0.001). Similarly, greater proportions of patients experienced maintenance or improvement in KCCQ-OS according to cutoff values (>;5 points [63.5% vs 46.6%; P&lt;0.001], >;10 points [74.6% vs 60.7%; P&lt;0.01]). Additionally, least squares (LS) mean difference in change from baseline in KCCQ subdomains, and in 6-MWT and KCCQ-OS across prespecified subgroups, favored vutrisiran versus placebo. Benefits observed with vutrisiran were similar in the monotherapy population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Vutrisiran maintained or improved functional capacity, health status, and QOL in more patients with ATTR-CM versus placebo over 30 months.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099774/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40099774</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.454>10.1016/j.jacc.2025.03.454</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099774</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Farooq H Sheikh</dc:creator>
<dc:creator>Gilbert Habib</dc:creator>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:creator>Ugochukwu O Egolum</dc:creator>
<dc:creator>Simone Longhi</dc:creator>
<dc:creator>Chongshu Chen</dc:creator>
<dc:creator>Emre Aldinc</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy</dc:title>
<dc:identifier>pmid:40099774</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.454</dc:identifier>
</item>
<item>
<title>Nrf3-Mediated Mitochondrial Superoxide Promotes Cardiomyocyte Apoptosis and Impairs Cardiac Functions by Suppressing Pitx2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099370/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Nrf3 promotes injury-induced CM apoptosis and deteriorates cardiac functions by increasing mitochondrial ROS production through suppressing Pitx2 expression. Targeting the Nrf3-Pitx2-mitochondrial ROS signal axis may therefore represent a novel therapeutic approach for MI treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18. doi: 10.1161/CIRCULATIONAHA.124.070286. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Myocardial infarction (MI) elicits mitochondria reactive oxygen species (ROS) production and cardiomyocyte (CM) apoptosis. Nrf3 (nuclear factor erythroid 2-related factor 3) has an established role in regulating redox signaling and tissue homeostasis. Here, we aimed to evaluate the role and mechanism of Nrf3 in injury-induced pathological cardiac remodeling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Global (Nrf3-KO) and CM-specific (Nrf3<sup>△CM</sup>) Nrf3 knockout mice were subjected to MI or ischemia/reperfusion injury, followed by functional and histopathological analysis. Primary neonatal mouse and rat ventricular myocytes and CMs derived from human induced pluripotent stem cells were used to evaluate the impact of Nrf3 on CM apoptosis and mitochondrial ROS production. Chromatin immunoprecipitation sequencing and immunoprecipitation-mass spectrometry analysis were used to uncover potential targets of Nrf3. MitoParaquat administration and CM-specific adeno-associated virus vectors were used to further confirm the <i>i</i>n vivo relevance of the identified signal pathways.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Nrf3 was expressed mainly in CMs in healthy human hearts, and an increased level of Nrf3 was observed in CMs within the border zone of infarcted human hearts and murine cardiac tissues after MI. Both global and CM-specific Nrf3 knockout significantly decreased injury-induced mitochondrial ROS production, CM apoptosis, and pathological cardiac remodeling, consequently improving cardiac functions. In addition, cardiac-specific Nrf3 overexpression reversed the ameliorative cardiac phenotypes observed in Nrf3-KO mice. Functional studies showed that Nrf3 promoted neonatal mouse ventricular myocyte, neonatal rat ventricular myocyte, and CMs derived from human induced pluripotent stem cell apoptosis by increasing mitochondrial ROS production. Critically, augmenting mitochondrial ROS with MitoParaquat blunted the beneficial effects of Nrf3 deletion on cardiac function and remodeling. Mechanistically, a redox regulator Pitx2 (paired-like homeodomain transcription factor 2) was identified as one of the main target genes of Nrf3. Specifically, Nrf3 binds to <i>Pitx2</i> promoter, where it increases DNA methylation through recruiting heterogeneous nuclear ribonucleoprotein K and DNA-methyltransferase 1 complex, thereby inhibiting Pitx2 expression. CM-specific knockdown of Pitx2 blunted the beneficial effects of Nrf3 deletion on cardiac function and remodeling, and cardiac-specific Pitx2 overexpression attenuated MI-induced mitochondrial ROS production and CM apoptosis, as well as preserved cardiac functions after MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Nrf3 promotes injury-induced CM apoptosis and deteriorates cardiac functions by increasing mitochondrial ROS production through suppressing Pitx2 expression. Targeting the Nrf3-Pitx2-mitochondrial ROS signal axis may therefore represent a novel therapeutic approach for MI treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099370/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40099370</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070286>10.1161/CIRCULATIONAHA.124.070286</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099370</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Qishan Chen</dc:creator>
<dc:creator>Ancheng Zheng</dc:creator>
<dc:creator>Xiaolei Xu</dc:creator>
<dc:creator>Zhenning Shi</dc:creator>
<dc:creator>Mei Yang</dc:creator>
<dc:creator>Shasha Sun</dc:creator>
<dc:creator>Leyu Wang</dc:creator>
<dc:creator>Yumeng Wang</dc:creator>
<dc:creator>Haige Zhao</dc:creator>
<dc:creator>Qingzhong Xiao</dc:creator>
<dc:creator>Li Zhang</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Nrf3-Mediated Mitochondrial Superoxide Promotes Cardiomyocyte Apoptosis and Impairs Cardiac Functions by Suppressing Pitx2</dc:title>
<dc:identifier>pmid:40099370</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070286</dc:identifier>
</item>
<item>
<title>Atrial Translocation of &lt;em>;Porphyromonas gingivalis&lt;/em>; Exacerbates Atrial Fibrosis and Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099365/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: P gingivalis translocation to the left atrium correlates with the clinical severity of periodontitis, which may exacerbate atrial fibrosis and AF. Atrial translocation of P gingivalis is a potential pathway explaining the causal relationship between periodontitis and AF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18. doi: 10.1161/CIRCULATIONAHA.124.071310. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Recent studies have indicated an association between periodontitis and atrial fibrillation (AF), although the underlying mechanisms remain unclear. <i>Porphyromonas gingivalis</i> is a causative agent of periodontal disease and is highly pathogenic. This study focused on <i>P gingivalis</i> and aimed to investigate the relationship among periodontitis, atrial translocation of <i>P</i> <i>gingivalis</i>, and atrial fibrosis and AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: An experiment was conducted using <i>P</i> <i>gingivalis</i>-infected C57BL/6J mice, in which <i>P</i> <i>gingivalis</i> was inoculated into the pulp of the molars. Immunohistochemistry was used to visualize the localization of <i>P</i> <i>gingivalis</i>, and loop-mediated isothermal amplification was employed to detect <i>P</i> <i>gingivalis</i> DNA in the left atrium. AF inducibility was examined by intracardiac stimulation. Moreover, left atrial appendage specimens were obtained from 68 patients with AF. A periodontal examination was conducted before the surgery, and the periodontal epithelial surface area and periodontal inflamed surface area, which are quantitative indices used to determine the clinical severity of periodontitis, were measured. The bacterial number of <i>P</i> <i>gingivalis</i> in human atrial tissue was analyzed via quantitative polymerase chain reaction. Atrial fibrosis was assessed using Azan-Mallory staining.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The translocation path of <i>P</i> <i>gingivalis</i> from the dental granuloma to the left atrium via the circulatory system was demonstrated by immunohistochemistry and loop-mediated isothermal amplification in <i>P</i> <i>gingivalis</i>-infected mice, which showed a higher degree of atrial fibrosis (21.9% versus 16.3%; <i>P</i>=0.0003) and a higher AF inducibility (30.0% versus 5.0%; <i>P</i>=0.04) than the control mice. Upregulation of GAL3 (galectin 3) and transforming growth factor-beta 1 in the left atrium was observed in <i>P</i> <i>gingivalis</i>-infected mice. Moreover, immunohistochemistry revealed that <i>P</i> <i>gingivalis</i> was also present in human atrial tissue. The number of <i>P</i> <i>gingivalis</i> in the human atrial tissue was positively correlated with periodontal epithelial surface area (ρ=0.35; <i>P</i>=0.004), periodontal inflamed surface area (ρ=0.52, <i>P</i>&lt;0.0001), and the degree of atrial fibrosis (ρ=0.38; <i>P</i>=0.002).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: <i>P</i> <i>gingivalis</i> translocation to the left atrium correlates with the clinical severity of periodontitis, which may exacerbate atrial fibrosis and AF. Atrial translocation of <i>P</i> <i>gingivalis</i> is a potential pathway explaining the causal relationship between periodontitis and AF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099365/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40099365</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071310>10.1161/CIRCULATIONAHA.124.071310</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099365</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Shunsuke Miyauchi</dc:creator>
<dc:creator>Miki Kawada-Matsuo</dc:creator>
<dc:creator>Hisako Furusho</dc:creator>
<dc:creator>Hiromi Nishi</dc:creator>
<dc:creator>Ayako Nakajima</dc:creator>
<dc:creator>Pham Trong Phat</dc:creator>
<dc:creator>Fumie Shiba</dc:creator>
<dc:creator>Masae Kitagawa</dc:creator>
<dc:creator>Kazuhisa Ouhara</dc:creator>
<dc:creator>Noboru Oda</dc:creator>
<dc:creator>Takehito Tokuyama</dc:creator>
<dc:creator>Yousaku Okubo</dc:creator>
<dc:creator>Sho Okamura</dc:creator>
<dc:creator>Taiichi Takasaki</dc:creator>
<dc:creator>Shinya Takahashi</dc:creator>
<dc:creator>Toru Hiyama</dc:creator>
<dc:creator>Hiroyuki Kawaguchi</dc:creator>
<dc:creator>Hitoshi Komatsuzawa</dc:creator>
<dc:creator>Mutsumi Miyauchi</dc:creator>
<dc:creator>Yukiko Nakano</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Atrial Translocation of &lt;em>;Porphyromonas gingivalis&lt;/em>; Exacerbates Atrial Fibrosis and Atrial Fibrillation</dc:title>
<dc:identifier>pmid:40099365</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071310</dc:identifier>
</item>
<item>
<title>A Novel Hidden Protein p-414aa Encoded by &lt;em>;circSETD2(14,15&lt;/em>;) Inhibits Vascular Remodeling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099364/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We uncover a novel hidden protein derived from circSETD2(14,15), called p-414aa, that inhibits vascular remodeling. CircSETD2(14,15) and p-414aa may serve as potential therapeutic targets for vascular remodeling diseases.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18. doi: 10.1161/CIRCULATIONAHA.124.070243. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Phenotypic switching of vascular smooth muscle cells (VSMCs), leading to neointimal hyperplasia, is a fundamental cause of vascular remodeling diseases such as atherosclerosis and hypertension. Novel hidden proteins encoded by circular RNAs play crucial roles in disease progression, yet their involvement in vascular remodeling diseases has not been comprehensively studied. This study identifies a novel protein derived from a circular RNA in VSMCs and demonstrates its potential role in regulating vascular remodeling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Cell proliferation assays were performed to investigate the effects of <i>circSETD2(14,15</i>) on VSMC proliferation. Techniques such as vector construction, immunoprecipitation-mass spectrometry, and dual-luciferase reporter gene were used to confirm that <i>circSETD2(14,15</i>) encoded a novel protein, p-414aa. The interaction between p-414aa and HuR (human antigen R) was validated with techniques such as coimmunoprecipitation, mass spectrometry, and proximity ligation assay. Through experiments including RNA sequencing and RNA immunoprecipitation, the interaction between HuR and <i>C-FOS</i> (C-Fos proto-oncogene) mRNA was revealed. The role of p-414aa in neointimal hyperplasia was assessed with a carotid artery ligation model in male mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overexpression of <i>circSETD2(14,15</i>) inhibits VSMC phenotypic switching. The novel protein p-414aa, encoded by <i>circSETD2(14,15</i>), interacts with HuR to reduce <i>C-FOS</i> mRNA stability, thereby suppressing VSMC proliferation and ultimately inhibiting neointimal hyperplasia in male mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We uncover a novel hidden protein derived from <i>circSETD2(14,15</i>), called p-414aa, that inhibits vascular remodeling. <i>CircSETD2(14,15</i>) and p-414aa may serve as potential therapeutic targets for vascular remodeling diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099364/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40099364</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070243>10.1161/CIRCULATIONAHA.124.070243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099364</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Si-Fan Wang</dc:creator>
<dc:creator>Li-Yun Yang</dc:creator>
<dc:creator>An-Qi Zhao</dc:creator>
<dc:creator>Zhao-Yi Wang</dc:creator>
<dc:creator>Sen Wang</dc:creator>
<dc:creator>Miao Gong</dc:creator>
<dc:creator>Ming-Qi Zheng</dc:creator>
<dc:creator>Gang Liu</dc:creator>
<dc:creator>Shu-Yan Yang</dc:creator>
<dc:creator>Jia-Jie Lin</dc:creator>
<dc:creator>Shao-Guang Sun</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Novel Hidden Protein p-414aa Encoded by &lt;em>;circSETD2(14,15&lt;/em>;) Inhibits Vascular Remodeling</dc:title>
<dc:identifier>pmid:40099364</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070243</dc:identifier>
</item>
<item>
<title>Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in China: Same, but Different</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099356/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Qual Outcomes. 2025 Mar 18:e011887. doi: 10.1161/CIRCOUTCOMES.125.011887. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099356/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40099356</a> | DOI:<a href=https://doi.org/10.1161/CIRCOUTCOMES.125.011887>10.1161/CIRCOUTCOMES.125.011887</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099356</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Derrick Y Tam</dc:creator>
<dc:creator>Harindra C Wijeysundera</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular quality and outcomes</dc:source>
<dc:title>Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in China: Same, but Different</dc:title>
<dc:identifier>pmid:40099356</dc:identifier>
<dc:identifier>doi:10.1161/CIRCOUTCOMES.125.011887</dc:identifier>
</item>
<item>
<title>Cost-Effectiveness of Aortic Valve Replacement in Low- and Intermediate-Risk Chinese Patients With Severe Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099355/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The risk-based strategy and universal TAVR appeared not to be cost-effective versus universal SAVR in low- and intermediate-risk patients with severe aortic stenosis in China.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Qual Outcomes. 2025 Mar 18:e010858. doi: 10.1161/CIRCOUTCOMES.124.010858. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Transcatheter aortic valve replacement (TAVR) remains debated as an alternative to surgical aortic valve replacement (SAVR). We aimed to evaluate the cost-effectiveness of aortic valve replacement strategies in low- and intermediate-risk patients with severe aortic stenosis in China.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A decision-analytic model combining decision tree and Markov model was developed to compare outcomes of universal SAVR, universal TAVR, and a risk-based strategy (SAVR in low-risk patients and TAVR in intermediate-risk patients) in a hypothetical cohort of 75-year-old patients with aortic stenosis within the perspective of the Chinese health care system. A meta-analysis was performed to derive the clinical inputs; the 2019 to 2021 claims data from Shaanxi Province were used for cost analysis, and quality of life was measured using EuroQoL-5D. One-way and probabilistic (10 000 Monte Carlo simulations) sensitivity analyses were conducted to examine the robustness of model results. Primary outcomes included total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Universal TAVR gained the most QALYs (6.76 QALYs) with the highest costs (USD 58 949). Compared with universal SAVR, the risk-based strategy gained 0.12 additional QALYs at higher costs (USD 14 046); the ICER (117 048 USD/QALY) exceeded the willingness-to-pay threshold (37 657 USD/QALY, 3-fold gross domestic product per capita in China). The ICER of universal TAVR versus universal SAVR (80 526 USD/QALY) also exceeded the willingness-to-pay threshold. Sensitivity analysis showed that universal TAVR would be cost-effective if TAVR valve costs were &lt;USD 21 477 (>;44.23% cost reduction). Subgroup analysis showed that universal TAVR and risk-based strategy remained not cost-effective compared with universal SAVR in both low-risk (ICER of 64 414 USD/QALY) and intermediate-risk (ICER of 124 851 USD/QALY) patients. In 10 000 Monte Carlo simulations, the probabilities of being cost-effective for universal SAVR, universal TAVR, and risk-based strategy were 89.81%, 10.14%, and 0.05%, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The risk-based strategy and universal TAVR appeared not to be cost-effective versus universal SAVR in low- and intermediate-risk patients with severe aortic stenosis in China.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099355/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40099355</a> | DOI:<a href=https://doi.org/10.1161/CIRCOUTCOMES.124.010858>10.1161/CIRCOUTCOMES.124.010858</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099355</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Jin Peng</dc:creator>
<dc:creator>Xinglong Zheng</dc:creator>
<dc:creator>Minghuan Jiang</dc:creator>
<dc:creator>Xuelin Yao</dc:creator>
<dc:creator>Yue Ma</dc:creator>
<dc:creator>Mao Fu</dc:creator>
<dc:creator>Tao Ma</dc:creator>
<dc:creator>Xiaolong Shang</dc:creator>
<dc:creator>Yang Yan</dc:creator>
<dc:creator>Vinod H Thourani</dc:creator>
<dc:creator>Yu Fang</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular quality and outcomes</dc:source>
<dc:title>Cost-Effectiveness of Aortic Valve Replacement in Low- and Intermediate-Risk Chinese Patients With Severe Aortic Stenosis</dc:title>
<dc:identifier>pmid:40099355</dc:identifier>
<dc:identifier>doi:10.1161/CIRCOUTCOMES.124.010858</dc:identifier>
</item>
<item>
<title>From diagnosis to surgery: managing left ventricular pseudo-aneurysm with cardiac computed tomography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40098610/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Case Rep. 2025 Mar 5;9(3):ytaf116. doi: 10.1093/ehjcr/ytaf116. eCollection 2025 Mar.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40098610/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40098610</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11911319/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">PMC11911319</a> | DOI:<a href=https://doi.org/10.1093/ehjcr/ytaf116>10.1093/ehjcr/ytaf116</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40098610</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Fábio Sousa Nunes</dc:creator>
<dc:creator>Mariana Ribeiro Silva</dc:creator>
<dc:creator>Catarina Relvas Novo</dc:creator>
<dc:creator>Nuno Dias Ferreira</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>European heart journal. Case reports</dc:source>
<dc:title>From diagnosis to surgery: managing left ventricular pseudo-aneurysm with cardiac computed tomography</dc:title>
<dc:identifier>pmid:40098610</dc:identifier>
<dc:identifier>pmc:PMC11911319</dc:identifier>
<dc:identifier>doi:10.1093/ehjcr/ytaf116</dc:identifier>
</item>
<item>
<title>Right haemothorax secondary to pulmonary vein laceration following left-sided pacemaker implantation: a case report</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40098609/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>BACKGROUND: Lead perforation is a rare but potentially fatal complication of cardiac device implantation. Atrial lead perforations, though less common than ventricular ones, can have severe consequences, especially in elderly patients with underlying structural heart disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Case Rep. 2025 Feb 25;9(3):ytaf093. doi: 10.1093/ehjcr/ytaf093. eCollection 2025 Mar.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lead perforation is a rare but potentially fatal complication of cardiac device implantation. Atrial lead perforations, though less common than ventricular ones, can have severe consequences, especially in elderly patients with underlying structural heart disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CASE SUMMARY: An 83-year-old male with amyloid and valvular cardiomyopathy underwent dual-chamber pacemaker implantation for third-degree atrioventricular block following transcatheter aortic valve implantation. The active-fixation atrial lead was positioned on the right atrial free wall. Six hours post-implantation, the patient developed haemodynamic instability. Echocardiography revealed a small pericardial effusion, while pacemaker interrogation showed an increased atrial pacing threshold. Chest imaging demonstrated a moderate right haemothorax. Initially, conservative management was recommended. However, the patient's condition deteriorated, progressing to cardiac arrest requiring brief cardiopulmonary resuscitation. Emergency sternotomy revealed a large right haemothorax and laceration of the right upper pulmonary vein in contact with the atrial lead screw. The laceration was repaired, and the atrial lead was repositioned. The patient recovered well and was discharged 5 days after surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DISCUSSION: Lead perforation is an uncommon but potentially severe complication of pacemaker implantation, with an incidence of 0.5-1% of cases. Several risk factors have been identified, including advanced age, low body mass index, atrial remodelling, and lateral lead placement. In this case, the atrial lead perforation extended from the atrial wall to the right superior pulmonary vein. This case underscores the potential risks associated with lateral lead positioning in geriatric patients and emphasizes the necessity for meticulous lead placement and vigilant post-implantation monitoring to mitigate complications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40098609/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40098609</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11911154/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">PMC11911154</a> | DOI:<a href=https://doi.org/10.1093/ehjcr/ytaf093>10.1093/ehjcr/ytaf093</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40098609</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Simon Fitouchi</dc:creator>
<dc:creator>Loïc Faucher</dc:creator>
<dc:creator>Aissam Labani</dc:creator>
<dc:creator>Laurence Jesel</dc:creator>
<dc:creator>Halim Marzak</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>European heart journal. Case reports</dc:source>
<dc:title>Right haemothorax secondary to pulmonary vein laceration following left-sided pacemaker implantation: a case report</dc:title>
<dc:identifier>pmid:40098609</dc:identifier>
<dc:identifier>pmc:PMC11911154</dc:identifier>
<dc:identifier>doi:10.1093/ehjcr/ytaf093</dc:identifier>
</item>
<item>
<title>Perioperative management and inflammatory marker monitoring in a cardiac surgery patient treated with tocilizumab: a case report of successful surgical aortic valve replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40098608/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>BACKGROUND: Interleukin (IL)-6 is associated with wound healing and infection response. Tocilizumab (TCZ) is a monoclonal antibody against the IL-6 receptor, interfering with its signalling pathway. However, reports on patients treated with TCZ undergoing cardiac surgery are limited.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Case Rep. 2025 Feb 24;9(3):ytaf085. doi: 10.1093/ehjcr/ytaf085. eCollection 2025 Mar.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Interleukin (IL)-6 is associated with wound healing and infection response. Tocilizumab (TCZ) is a monoclonal antibody against the IL-6 receptor, interfering with its signalling pathway. However, reports on patients treated with TCZ undergoing cardiac surgery are limited.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CASE SUMMARY: A 73-year-old man with Castleman disease, treated with TCZ, underwent surgical aortic valve replacement via median sternotomy for aortic valve regurgitation with exertional shortness of breath. Comprehensive measures for preventing surgical site infection along with close examination were implemented during the perioperative period. Tocilizumab was discontinued 26 days before surgery and resumed 30 days after surgery, during which plasma IL-6 levels decreased. There was no evidence of infection or exacerbation of Castleman disease. Vascular endothelial growth factor levels increased before an increase in C-reactive protein levels following hospital discharge and prior to TCZ resumption.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DISCUSSION: Meticulous perioperative management with a multi-disciplinary approach is crucial during the cessation of TCZ for cardiac surgery. Changes in vascular endothelial growth factor levels may serve as an early predictor of underlying disease exacerbation after TCZ cessation for surgery.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40098608/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40098608</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11911119/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">PMC11911119</a> | DOI:<a href=https://doi.org/10.1093/ehjcr/ytaf085>10.1093/ehjcr/ytaf085</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40098608</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Masashi Toyama</dc:creator>
<dc:creator>Masato Nakayama</dc:creator>
<dc:creator>Tomonari Uemura</dc:creator>
<dc:creator>Shingo Kurahashi</dc:creator>
<dc:creator>Bunmei Sato</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>European heart journal. Case reports</dc:source>
<dc:title>Perioperative management and inflammatory marker monitoring in a cardiac surgery patient treated with tocilizumab: a case report of successful surgical aortic valve replacement</dc:title>
<dc:identifier>pmid:40098608</dc:identifier>
<dc:identifier>pmc:PMC11911119</dc:identifier>
<dc:identifier>doi:10.1093/ehjcr/ytaf085</dc:identifier>
</item>
<item>
<title>A case of effective multi-site radiofrequency ablation of premature ventricular complexes in the left ventricular summit</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40098607/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Case Rep. 2025 Feb 26;9(3):ytaf106. doi: 10.1093/ehjcr/ytaf106. eCollection 2025 Mar.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40098607/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40098607</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11911118/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">PMC11911118</a> | DOI:<a href=https://doi.org/10.1093/ehjcr/ytaf106>10.1093/ehjcr/ytaf106</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40098607</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Emídio Mata</dc:creator>
<dc:creator>Sílvia Ribeiro</dc:creator>
<dc:creator>Lucy Calvo</dc:creator>
<dc:creator>Víctor Sanfins</dc:creator>
<dc:creator>António Lourenço</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>European heart journal. Case reports</dc:source>
<dc:title>A case of effective multi-site radiofrequency ablation of premature ventricular complexes in the left ventricular summit</dc:title>
<dc:identifier>pmid:40098607</dc:identifier>
<dc:identifier>pmc:PMC11911118</dc:identifier>
<dc:identifier>doi:10.1093/ehjcr/ytaf106</dc:identifier>
</item>
<item>
<title>Covered Stent Treatment for Sinus Venosus Atrial Septal Defects: Early Promise and Potential Limitations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40096298/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318161149&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18;151(11):757-759. doi: 10.1161/CIRCULATIONAHA.124.072394. Epub 2025 Mar 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40096298/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318161149&v=2.18.0.post9+e462414">40096298</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072394>10.1161/CIRCULATIONAHA.124.072394</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40096298</guid>
<pubDate>Mon, 17 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Glen Van Arsdell</dc:creator>
<dc:creator>Doff B McElhinney</dc:creator>
<dc:date>2025-03-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Covered Stent Treatment for Sinus Venosus Atrial Septal Defects: Early Promise and Potential Limitations</dc:title>
<dc:identifier>pmid:40096298</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072394</dc:identifier>
</item>





























</channel>
</rss>